Compare MSAI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MSAI | BOLD |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 26.2M |
| IPO Year | N/A | 2024 |
| Metric | MSAI | BOLD |
|---|---|---|
| Price | $0.50 | $1.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.75 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 2.1M | 185.6K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,563,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $106.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $1.00 |
| 52 Week High | $3.33 | $3.45 |
| Indicator | MSAI | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 49.33 |
| Support Level | $0.53 | $1.11 |
| Resistance Level | $0.64 | $1.20 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 3.35 | 85.00 |
MultiSensor AI Holdings Inc build and deploy intelligent multi-sensing platforms incorporating edge and cloud software solutions that leverage artificial intelligence (AI). It is a provider of sensing systems built around high-resolution thermal imagers, visible and acoustic imagers, as well as vibration and laser spectroscopy sensors, that perceive and measure heat, sound, vibration, and gas in industrial assets and the surrounding environment, helping companies gain insight to protect and manage their most important assets and infrastructure. It also offers a wide range of form factors for its sensor devices, including, among other form factors, small to large handheld designs with built-in displays and controls, and fixed-mounted single- and multi-sensor camera sensor systems.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.